Olivier Marcq

Senior Vice President - CMC at Tubulis

Speaker

After more than two decades in the US and 18 years in bioconjugates research, development and manufacturing across vaccines and ADC platforms at startups and big pharma organizations, Dr Marcq, joined Tubulis in 2022. The mission: to create a CMC organization supporting the in-house grown pipeline based on Tubulis proprietary conjugation and linker payload technologies. Tubulis will count two active clinical programs by early 2025 and a growing portfolio. Tubulis has also developed strong relations with one product licensee and two technology licensees.